Amarin Corp Plc (AMRN)

[NewMoney]

AMARIN CHARGED WITH SECURITIES FRAUD!

Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Amarin Corporation plc

If you purchased shares of Amarin during the Class Period and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 825 East Gate Boulevard, Suite 300, Garden City, NY at [phone], by e-mail to [e-mail], or at: http://www.rigrodskylong.com/investigations/amarin-corporation-plc-amrn.

According to the Complaint, in a Briefing Document published on October 11, 2013, the FDA both summarized its significant doubt expressed to Amarin in July 2008 that the reduction of TGs alone evidenced an improved risk of cardiac issues and stated that based on published test results first available to Amarin in 2010 that there was little indication that a reduction in TGs alone would improve the incidence of cardiac events. As a result, on October 16, 2013, an Advisory Committee rejected Amarin’s new drug application based on its ANCHOR study, adopting the FDA’s position that the ANCHOR study itself was not indicative of the efficacy of the drug to reduce severe cardiovascular events.

On this news, shares in Amarin dropped more than 61%, closing at $2.01 per share on October 17, 2013, on extraordinarily heavy trading volume of over 105 million shares.




http://ih.advfn.com/p.php?pid=nmona&article=60140847